Prolonged viral shedding of SARS-CoV-2 in an immunocompromised patient
The duration of viral shedding of SARS-CoV-2 is usually less than 10 days. We experienced a COVID-19 case with prolonged viral shedding for 2 months. His cell mediated immunity has been depressed (CD4+T cell <100/μl) due to advanced malignant lymphoma and chemotherapy which had been completed 4 m...
Saved in:
Published in | Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy Vol. 27; no. 2; pp. 387 - 389 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Netherlands
Elsevier Ltd
01.02.2021
Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd |
Subjects | |
Online Access | Get full text |
ISSN | 1341-321X 1437-7780 1437-7780 |
DOI | 10.1016/j.jiac.2020.12.001 |
Cover
Summary: | The duration of viral shedding of SARS-CoV-2 is usually less than 10 days. We experienced a COVID-19 case with prolonged viral shedding for 2 months. His cell mediated immunity has been depressed (CD4+T cell <100/μl) due to advanced malignant lymphoma and chemotherapy which had been completed 4 months prior to the onset of symptoms of COVID-19. We administered several treatments against COVID-19, however the results of Polymerase Chain Reaction (PCR) from nasopharyngeal specimens remained positive to SARS-CoV-2 for 2 months. Moreover, virus isolation assays performed on Day 59 also remained positive. He was finally discharged on Day 69 with two consecutive negative PCR results for SARS-CoV-2. Immunocompromised status may prolong viral shedding and it is therefore important for the clinician to take into account this when assessing such patients. |
---|---|
Bibliography: | ObjectType-Case Study-2 SourceType-Scholarly Journals-1 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3 |
ISSN: | 1341-321X 1437-7780 1437-7780 |
DOI: | 10.1016/j.jiac.2020.12.001 |